Clinical practice guidelines for the diagnosis and treatment of cutaneous leishmaniasis in Turkey

dc.authorid0000-0002-4303-699X
dc.authorid0000-0003-1376-1573
dc.authorid0000-0003-1247-3932
dc.authorid0000-0001-7059-5474
dc.contributor.authorUzun, Soner
dc.contributor.authorGurel, Mehmet S.
dc.contributor.authorDurdu, Murat
dc.contributor.authorAkyol, Melih
dc.contributor.authorKaraman, Bilge Fettahlioglu
dc.contributor.authorAksoy, Mustafa
dc.contributor.authorAytekin, Sema
dc.date.accessioned2025-05-10T19:40:05Z
dc.date.issued2018
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractBackground Cutaneous leishmaniasis ( CL) is a vector- born parasitic disease characterized by various skin lesions that cause disfiguration if healed spontaneously. Although CL has been endemic for many years in the southern regions of Turkey, an increasing incidence in nonendemic regions is being observed due to returning travelers and, more recently, due to Syrian refugees. Thus far, a limited number of national guidelines have been proposed, but no common Turkish consensus has emerged. Objectives The aim of this study was to develop diagnostic and therapeutic guidelines for the management of CL in Turkey. Methods This guideline is a consensus text prepared by 18 experienced CL specialists who have been working for many years in areas where the disease is endemic. The Delphi method was used to determine expert group consensus. Initially, a comprehensive list of items about CL was identified, and consensus was built from feedback provided by expert participants from the preceding rounds. Results Evidence- based and expert- based recommendations through diagnostic and therapeutic algorithms according to local availability and conditions are outlined. Conclusion Because CL can mimic many other skin diseases, early diagnosis and early treatment are very important to prevent complications and spread of the disease. The fastest and easiest diagnostic method is the leishmanial smear. The most common treatment is the use of local or systemic pentavalent antimony compounds.
dc.identifier.doi10.1111/ijd.14002
dc.identifier.endpage982
dc.identifier.issn0011-9059
dc.identifier.issn1365-4632
dc.identifier.issue8
dc.identifier.pmid29663351
dc.identifier.scopusqualityQ1
dc.identifier.startpage973
dc.identifier.urihttps://doi.org/10.1111/ijd.14002
dc.identifier.urihttps://hdl.handle.net/20.500.14730/9881
dc.identifier.volume57
dc.identifier.wosWOS:000437833900024
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofInternational Journal of Dermatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectIntralesional Sodium Stibogluconate
dc.subjectMeglumine Antimoniate
dc.subjectCryotherapy
dc.subjectDonovani
dc.subjectSanliurfa
dc.subjectEfficacy
dc.subjectFeatures
dc.subjectTrial
dc.titleClinical practice guidelines for the diagnosis and treatment of cutaneous leishmaniasis in Turkey
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
9881.pdf
Boyut:
314.63 KB
Biçim:
Adobe Portable Document Format